Source Managed Care Mag. A surge of new MS treatments have been for the relapsing-remitting form of the disease. A new drug that targets CD20-positive B cells may change that. Read on.
Posts Categorized: MS News
Is it possible to get stronger just by thinking about exercise?
Source BBC: Could simply thinking about exercise – without so much as lifting a finger – really do the trick? It sounds incredibly unlikely, but ‘motor imagery’ is a technique often used by top athletes, and some studies suggest that you can use it to improve your strength by mental training alone. Trust Me, I’m… Read more »
Scientists have discovered never-before-seen vessels in the brain
Source Science Alert: Scientists in the US have discovered a new series of lymphatic vessels in the body that link the brain to the immune system – a connection researchers had previously thought didn’t exist. The discovery could not only prompt a rewrite of the textbooks, it might also lead to a new understanding of… Read more »
New report calls for neurology care to be delivered closer to home
Source MS Trust: The Thames Valley Strategic Clinical Network launches a new report (link is external) calling for improvements in neurological services provided in the community. The report slams the current provision of care for people with long-term neurological conditions, describing it as unsatisfactory from all perspectives, including those of patients, carers and commissioners (the… Read more »
Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%
Source Labiotech.eu Biogen and AbbVie have been granted EU marketing authorization forZinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Read on.
Siponimod Effective in Reducing Disease Activity in Relapsing=-Remitting MS
Source Neurology Advisor: Results from the 24-month extension of the phase 2 BOLD study demonstrated no new safety concerns and low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated with siponimod. Read on.
Could the gut microbiome be a new therapeutic target for multiple sclerosis?
Source EurekAlert: New Rochelle, NY, July 6, 2016–An increasing number of clinical studies are pointing to a link between the autoimmune disease multiple sclerosis (MS) and the composition of microbes in the human gut, sparking new research on the gut microbiome as a potential target for MS treatment and prevention. Read on
MS – New therapy but a dilemma for patients
Source BBC News: There has been a widespread welcome for news that a new therapy involving stem cell transplants has halted or reversed the symptoms of advanced multiple sclerosis in a small number of patients. Read on.
Rituximab Better than Fingolimod for Preventing Relapses in Multiple Sclerosis Patients.
Rituximab Better than Fingolimod for Preventing Relapses in Multiple Sclerosis Patients. Source MD Preventing relapses for patients with highly active multiple sclerosis (MS) is more easily accomplished with rituximab than with fingolimod, according to findings published in the Annals of Neurology. Read on.
Myelination Relies on Mechanical Stimuli Like That Used for Bone Repair, Study finds.
Myelination Relies on Mechanical Stimuli Like That Used for Bone Repair, Study finds. Source Multiple Sclerosis News Today: Researchers at the University of Buffalo’s Hunter James Kelly Research Institute (HJKRI) discovered that the cells that form myelin in the nervous system respond to mechanical stimulation by activating molecules from a specific pathway, which are transferred… Read more »
